

1 Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral 2 heterogeneity to immune escape

3 Mahdi Golkaram,¹ Fengshen Kuo,² Sounak Gupta,³ Maria I. Carlo,⁴ Michael L. Salmans,¹ Raakhee Vijayaraghavan,¹
4 Cerise Tang,⁵ Vlad Makarov,^{2,5} Phillip Rappold,⁵ Kyle A. Blum,^{2,5,6} Chen Zhao,¹ Rami Mehio,¹ Shile Zhang,¹ Jim
5 Godsey,¹ Traci Pawlowski,¹ Renzo G. DiNatale,^{2,5,6} Luc GT Morris,⁷ Jeremy Durack,⁸ Paul Russo,⁶ Ritesh R. Kotecha,⁴
6 Jonathan Coleman,⁶ Ying-Bei Chen,³ Victor E Reuter,³ Robert J Motzer,⁴ Martin H. Voss,⁴ Li Liu,^{1,15,*} Ed Reznik,^{6,9,10,15,*}
7 Timothy A. Chan,^{2,11,12,13,14,15,*} and A. Ari Hakimi^{2,6,15,16,*}

8 ¹Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA

9 ²Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

10 ³Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

11 ⁴Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA

12 ⁵Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

13 ⁶Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

14 ⁷Department of Surgery, Head & Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

15 ⁸Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

16 ⁹Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

17 ¹⁰Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

18 ¹¹Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

19 ¹²Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA

20 ¹³Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

21 ¹⁴National Center for Regenerative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA

22 ¹⁵Senior author

23 ¹⁶Lead contact

24 *Correspondence: reznike@mskcc.org (E.R.), lliu3@illumina.com (L.L.), chant2@ccf.org (T.A.C.), hakimia@mskcc.org (A.A.H).

25

26

27 **Abstract**

28 **Background**

29 Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma (ccRCC) that
30 reflects the trajectory of evolution and influences clinical prognosis. Here we seek to elucidate
31 how ITH and tumor evolution during immune checkpoint inhibitor (ICI) treatment can lead to
32 therapy resistance.

33

34 **Methods**

35 Here, we spatiotemporally profiled the genomic and immunophenotypic characteristics of 29
36 ccRCC patients, including pre- and post-therapy samples from 17 ICI treated patients.

37 Deep multi-regional whole exome and transcriptome sequencing were performed on 29 patients
38 at different time points before and after ICI therapy. T cell repertoire was also monitored from
39 tissue and peripheral blood collected from a subset of patients to study T cell clonal expansion
40 during ICI therapy.

41

42 **Results**

43 Angiogenesis, lymphocytic infiltration, and myeloid infiltration varied significantly across regions
44 of the same patient, potentially confounding their utility as biomarkers of ICI response. Elevated
45 ITH associated with a constellation of both genomic features (HLA LOH, CDKN2A/B loss) and
46 microenvironmental features, including elevated myeloid expression, reduced peripheral T cell
47 receptor (TCR) diversity, and putative neoantigen depletion. Hypothesizing that ITH may itself
48 play a role in shaping ICI response, we derived a transcriptomic signature associated with

49 neoantigen depletion that strongly associated with response to ICI and targeted therapy treatment
50 in several independent clinical trial cohorts.

51

52 **Conclusions**

53 These results argue that genetic and immune heterogeneity jointly co-evolve and influence
54 response to ICI in ccRCC.

55

56 **Trial registration**

57 We completed a single-arm pilot study at Memorial Sloan Kettering Cancer Center (MSKCC;
58 ClinicalTrials.gov identifier NCT02595918) to examine the safety and feasibility of neoadjuvant
59 nivolumab in patients with localized RCC.

60

61 **Background**

62 Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney
63 cancer and demonstrates a high response rate to immune checkpoint inhibitors such as
64 nivolumab, pembrolizumab and ipilimumab [1-3]. However, only a subset of ccRCC patients
65 respond to ICI, and biomarkers for ICI response in other disease settings such as tumor mutation
66 burden, neoantigen load and mismatch repair deficiency do not associate with ICI response in
67 ccRCC [4-7]. Recently, several studies have identified transcriptomic microenvironmental
68 features including angiogenic gene expression, T-cell infiltration, and myeloid activation that
69 correlate with response or resistance to ICI and combination therapies in ccRCC [7-13]. This
70 suggests that the ccRCC microenvironment, in addition to genomic factors, influences ICI
71 response.

72 In parallel, recent work has demonstrated the prevalence of ITH in untreated ccRCC [14].
73 This study has largely focused on heterogeneity in the presence of key driver mutations and copy
74 number alterations and have demonstrated that ccRCC tumors follow one of a small number of
75 evolutionary trajectories, each of which are associated with distinct patterns of genomic ITH and
76 clinical prognosis. However, the potential for non-genomic heterogeneity in the tumor
77 microenvironment, including but not limited to variability in the amount and identity of immune
78 cells in spatially distinct regions of the same tumor is overlooked. Recently, we and others
79 described substantial heterogeneity in the tumor-microenvironment (TME) in several small
80 cohorts of ccRCC tumors both in the treatment-naïve and treatment-exposed settings, raising the
81 possibility that heterogeneity in the TME may itself shape the evolution of the tumor and its
82 likelihood to respond to therapy [15, 16].

83
84 In this study, we hypothesized ccRCC tumors with elevated ITH constitute a genomically
85 and immunologically distinct class of tumors, with distinguishing clonal/subclonal genomic
86 alterations, immunologic profiles, and therapeutic response trajectories. To test this hypothesis,
87 we utilize whole exome sequencing (WES), whole transcriptome sequencing (WTS), TCRseq,
88 and histopathologic multi-regional data across a cohort of untreated and ICI exposed patients
89 from a phase 2 clinical trial to reveal the molecular determinants of therapy response in ccRCC
90 (Fig. 1 and Table S1). Our integrated analysis demonstrated that ITH is highly correlated among
91 genomic, transcriptomic, and TME characteristics. ITH-high tumors are enriched for features
92 including SETD2 and PBRM1 mutations, HLA loss of heterozygosity (HLA LOH), and CDKN2A/B
93 loss. Immunologically, ITH-high tumors display a depletion of putative neoantigens, elevated
94 myeloid activation, and reduced T cell diversity, that are in aggregate associated with escape
95 from the anti-tumor immune response. Premised on these observations, we developed a

96 transcriptional signature for immune escape which correlates with distinct histopathologic patterns
97 and is associated with ICI resistance across several diverse clinical trial cohorts.

98

99 **Materials and Methods**

100 **Sample acquisition**

101 After acquiring informed consent and institutional review board approval from Memorial
102 Sloan Kettering Cancer Center (MSK), partial or radical nephrectomies were performed at MSK
103 (New York) and stored at the MSK Translational Kidney Research Program (TKRCP). Samples
104 were flash frozen and stored at -80 degrees Celsius prior to molecular characterization. Clinical
105 metadata was recorded for all tumor samples. All patients represent clear cell histology and were
106 treated via ICI alone or in combination with tyrosine kinase inhibitor (TKI). All treatments were
107 administered prior to surgery in a neo-adjuvant setting and biopsies were collected. Detailed
108 clinical data and treatment regimen for each patient is included in [Table S2](#).

109

110 **Untreated cohort**

111 Using and institutional database we identified six patients with advanced or metastatic
112 ccRCC that underwent nephrectomy with multiregional data available MR01,02,03,05,06, SC03.
113 Clinical and pathologic data is available in [Table S2](#).

114

115 **Neoadjuvant multiregional cohort**

116 This open-label, single-arm, pilot study was done at Memorial Sloan Kettering Cancer
117 Center and funded through the National Institute of Health's Cancer Therapy Evaluation Program
118 (CTEP). Patients received nivolumab (dose initially 3 mg/kg, then protocol amended to 240 mg

119 flat dose) every 2 weeks for 4 treatments. Surgery was planned 7-14 days after the last dose.
120 Prior to starting therapy, all patients had a kidney biopsy to confirm ccRCC, and tumor staging
121 with renal protocol MRI and CT of the chest. After 4 doses and prior to surgery, patients also had
122 a renal protocol MRI. Changes in primary tumor size were assessed according to Response
123 Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Resection of the primary tumor and
124 lymph nodes was done according to standard institutional procedures. From May 27, 2016, to
125 September 9, 2019, 21 patients were screened and 18 were enrolled into the study of which 17
126 had available genomic data. Baseline patient characteristics are in [Supplementary Table S2](#). All
127 patients had localized disease at time of enrollment and biopsy-proven clear cell RCC.
128 Perioperative and pathological details are included in [Supplementary Table S2](#). Median time to
129 nephrectomy after the last dose of nivolumab was 10.5 days (range, 9-13 days).

130

131 **Metastatic multiregional Cohort**

132 Using an institutional database, we identified 6 additional patients who had received ICI
133 prior to nephrectomy ([Supplementary Table S2](#)). All patients had metastatic disease at time of
134 ICI; two received anti-VEGF therapies before ICI.

135

136 **Multi-regional sampling**

137 For the prospective neoadjuvant trial and the “MR” samples single region biopsies were
138 obtained preoperatively. Following nephrectomy, tumor were bivalved and 5 regions were chosen:
139 One region from the tumor center and 4 from each quadrant (upper medial, upper later, lower
140 medial, lower lateral). Grossly necrotic or hemorrhagic regions were avoided. For the remaining
141 samples (those treated with definitive immunotherapy “SC”) regions were taken from distinct
142 regions of tumors separated by 1-2 cm avoiding grossly necrotic or hemorrhagic regions).

143

144 **Whole exome sequencing**

145 Libraries for whole exome sequencing were generated with TruSight Oncology DNA
146 Library Prep Kit with 40ng input DNA per sample. TruSight Oncology index PCR products were
147 directly used for enrichment and target exome enrichment was performed using the IDT xGen
148 Universal Blockers and IDT xGen Exome Research panel. A single-plex hybridization was done
149 overnight at 65°C. Accuclear dsDNA Ultra High Sensitivity assay (Biotium) was used for library
150 quantification of the post-enriched libraries. Post enrichment libraries were normalized using
151 bead-based normalization and pooled. Samples were sequenced with 101 bp paired-end reads
152 on Illumina NovaSeq™ 6000 S4 flow cell using the XP workflow for individual lane loading (12-
153 plex per lane). On average, each sample yielded 500 million reads and
154 MEDIAN_TARGET_COVERAGE depth of 360X.

155

156 **Whole transcriptome sequencing**

157 Libraries for whole transcriptome RNA-seq were generated with Illumina TruSeq Stranded
158 Total RNA. 100 ng RNA was used as input for Ribo-Zero rRNA Removal Kit, with Illumina TruSeq
159 RNA UD Indexes (96 indexes) for sample indexing. Qubit dsDNA High Sensitivity assay (Thermo
160 Fisher Scientific) was used for library quantification. Sequencing was done on Illumina
161 NovaSeq™ 6000 S2 (36-plex) or S4 (72-plex) flow cell with 76 bp paired-end sequencing to
162 produce ~200 million paired reads per library.

163

164 **T-cell repertoire sequencing**

165 Libraries for T-cell repertoire sequencing were generated with AmpliSeq for Illumina
166 Library PLUS paired with AmpliSeq cDNA Synthesis for Illumina with 100 ng RNA input per cDNA
167 synthesis reaction. The TCR beta-SR Panel was used for generating amplicons, and AmpliSeq
168 CD Indexes Set A for Illumina were used for sample barcodes. Qubit dsDNA High Sensitivity
169 assay (Thermo Fisher Scientific) was used for library quantification. Sequencing was done on the
170 NextSeq 550 (41-plex) with 151 bp paired-end sequencing to produce ~5 million paired reads per
171 library.

172

173 **WTS pipeline**

174 WTS raw read sequences were aligned against human genome assembly hg19 by STAR
175 2-pass alignment [17]. QC metrics, for example general sequencing statistics, gene feature and
176 body coverage, were then calculated based on the alignment result through RSeQC. WTS gene
177 level count values were computed by using the R package GenomicAlignments [18] over aligned
178 reads with UCSC KnownGene [19] in hg19 as the base gene model. The union counting mode
179 was used and only mapped paired reads after alignment quality filtering were considered. Finally,
180 gene level FPKM (Fragments Per Kilobase Million) and raw read count values were computed by
181 the R package DESeq2 [20].

182

183 **ESTIMATE**

184 The ESTIMATEScore, which is the estimate of the presence of stromal and immune cells
185 in tumor tissue, is calculated through the ESTIMATE R package [21] based on a given gene
186 expression profile in FPKM.

187

188 **Immune deconvolution analysis**

189 Two distinct popular computational methods, ssGSEA [22] and CIBERSORT [23], were
190 chosen for immune deconvolution analysis. Signature gene lists of immune cell types for ssGSEA
191 were obtained from Bindea et al. [24] and Senbabaoglu et al. [3]. ssGSEA takes the sample FPKM
192 WTS expression values as the input and computes an enrichment score for the given gene list of
193 immune cell type relative to all other genes in the transcriptome. On the other hand, CIBERSORT
194 also takes FPKM WTS expression values as the input but uses a signature gene expression
195 matrix of interest immune cell types instead to compute the infiltration level of each immune cell
196 type. The LM22 immune cell signature which was validated and published along with
197 CIBERSORT is used. We also used FRICTION [25] to deconvolute WTS into absolute CD8 and
198 CD4 T cells as well as CD19 B cells.

199

200 **HERV quantification**

201 We used WTS to quantify HERVs as described before [25]. Briefly, all WTS reads were
202 aligned (using STAR aligner with optimized multi mapping options) to a custom genome built were
203 human reference (hg19) and HERV specific reference are combined. Then reads aligned to non-
204 HERV genes are removed and the rest are annotated. 3 samples contained super high median
205 HERVs (Grubbs test $P < 0.05$) and removed for better visualization.

206

207 **WES analysis pipeline**

208 Raw sequencing data were aligned to the hg19 genome build using the Burrows-Wheeler
209 Aligner (BWA) version 0.7.17 [26]. Further indel realignment, base-quality score recalibration and
210 duplicate-read removal were performed using the Genome Analysis Toolkit (GATK) version 3.8
211 [27] following raw reads alignments guidelines [28]. VarScan 2 [29], Strelka v2.9.10 [30], Platypus

212 0.8.1 [31], Mutect2 – part of GATK 4.1.4.1 [28], Somatic Sniper version 1.0.5.0 (SNVs only), and
213 [32] were used for small variant calling and combination of 2 out of 5 callers are reported as per
214 Cancer Genome Atlas Research Network recommendations [33]. Variants were filtered using the
215 following criteria:

- 216 1. Tcov > 10 & Taf >=0.04 & Ncov > 7 & Naf <= 0.01 & Tac > 4 are set to Pass
- 217 2. Common SNPs are eliminated by comparison to snp142.vcf
- 218 3. Rare variants found in dbSNP are kept if Naf = 0
- 219 4. Variants with Tcov < 20 or Tac < 4 are marked as low_confidence
- 220 5. Only variants called by more than 1 caller are reported.
- 221 6. Common variables gnomAD v 2.1.1 are excluded.

222 Variants were annotated using Ensembl Variant Effect Predictor (VEP) [34]. Additional
223 optimization and filtering are applied for INDELS. INDELS in blacklisted regions
224 (<https://www.encodeproject.org/annotations/ENCSR636HFF/>) and low mappability regions (such
225 as repeat maskers) are excluded as per [35]. Combination of filtered SNV and INDELS are used
226 by maftools R package is used to generate oncoplots and summary plots, as per author's
227 recommendations

228 <https://www.bioconductor.org/packages/release/bioc/vignettes/maftools/inst/doc/maftools.html>

229 All nonsynonymous point mutations identified as above were translated into strings of 17
230 amino acids with the mutant amino acid situated centrally using a bioinformatics tool called
231 NAsseek. A sliding window method is used to identify the 8-11 amino acid substrings within the
232 mutant 17-mer that had a predicted MHC Class I binding affinity of ≤ 2 %Rank to one (or more)
233 of the patient-specific HLA alleles. Binding affinity for the mutant and corresponding wild type

234 nonamer is analyzed using NetMHCpan4.0 software. Only neoantigens with a TPM>1 are
235 considered to be expressed.

236 Allele-specific copy number analysis is done by the FACETS v.6.1 [36]. Allele specific HLA
237 loss is determined using LOHHLA as described before [37].

238

239 **RNA and TCR ITH scores**

240 Gene- and patient-wise intra-patient heterogeneity scores were calculated using multi-
241 region data. Data was first median-centered to remove any gene-level bias. For each gene, the
242 difference between each pair of samples from the same tumor were calculated. The median
243 difference between the paired-differences was then taken, yielding a gene-specific, patient-
244 specific measure of heterogeneity. This was repeated for all genes, across all tumors, generating
245 a matrix of gene by patient values. Gene intratumor heterogeneity values are summarized as the
246 median value per gene across all tumors in the cohort. Patient intratumor heterogeneity values
247 are summarized as the median value per tumor across all genes. Patient intratumor heterogeneity
248 values represent the expected value of the absolute log₂-fold change for a randomly chosen gene
249 within a given tumor.

250 TCR ITH score is defined as 1 – percentage of shared clonotypes across multiple regions
251 of tumor based on WTS. T cell clones are estimated using MiXCR application on Illumina
252 BaseSpace (<http://basespace.illumina.com/apps/>). Furthermore, all ITH scores are classified as
253 high versus low using the median as threshold.

254

255 **Distinction between dedicated TCRseq and TCR clones inferred from RNAseq using**
256 **MiXCR**

257 All TCR associated data analysis in this study (including tissue or PBMC) are based on
258 ultra-deep T cell repertoire sequencing (targeted TCRseq) to mitigate undersampling of T cell
259 clones except TCR ITH analysis in Fig. 3b where ITH associated with multiregional sequencing
260 is derived from MiXCR T cell estimates from RNAseq data due to the lack of multiregional TCRseq
261 for all patients.

262

263 **ccRCC evolutionary subtypes and intra-tumor DNA Heterogeneity Score**

264 DNA ITH score is calculated as the ratio of subclonal to clonal driver genomic alterations
265 including SNVs, INDELs, and SCNA [14]. A genomic alteration is defined to be subclonal if it is
266 present in less than half of the regions collected in each patient. Patients who enough DNA
267 biopsies are collected are classified into 1 of the 7 ccRCC evolutionary subtypes as described
268 before [14]. We used neighbor joining tree construction in ape package in R [38] for reconstruction
269 of tumor clones. TCGA ITH score was obtained from a previous study as measured by the number
270 of clones estimated per sample using PhyloWGS [39]. Briefly, PhyloWGS is a method to infer
271 tumor evolution evolutionary using the relationships between tumor subpopulations based on
272 variant allele frequencies while considering copy number alterations.

273

274 **HLA and TCR diversity**

275 Shannon entropy is calculated to define TCR diversity [40]. We used MiXCR application
276 on Illumina BaseSpace (<http://basespace.illumina.com/apps/>) for alignment and T cell clonotype
277 identification. Immunarch (<https://immunarch.com/>) [41] was used for downstream analysis
278 including visualization and data analysis. Morisita index [42] was used to measure clonotype
279 overlap. HLA diversity index is measured as adopted from [43] as described in [25].

280

281 **Neoantigen Depletion**

282 The fraction of neoantigens depleted is defined for each sample where pretreatment data
283 was available. We first calculated the neoantigen depletion as the number of neoantigens that
284 were undetectable after therapy but were detected pretreatment. The fraction of neoantigens
285 depleted was then defined as the ratio of the total number of depleted neoantigens over total
286 pretreatment neoantigens. To distinguish neoantigen depletion due to contraction (immune
287 elimination) from evasion, we exclude any neoantigens that were depleted without the presence
288 of HLA LOH (defects in antigen presentation machinery), or reduced expression i.e., $\log_2(\text{FC}) < -$
289 1 where FC is the fold change defined as the ratio of post treatment TPM over pretreatment TPM
290 after correction for tumor purity. Conversely, a neoantigen is annotated as deleted due to immune
291 elimination if $\log_2(\text{FC}) \geq 0$ and no HLA LOH was detected. Likewise, HERV editing is defined as
292 the median change in the expression of immunogenic HERVs compared to pre-treatment
293 expression. Immunogenic HERVs refers to HERV loci whose expression strongly correlates with
294 TIL abundance, $\text{FDR} < 0.05$.

295

296 **Weighted Gene Co-expression Network Analysis (WGCNA) and gene signature extraction**

297 We performed WGCNA [44] on all samples where the fraction of neoantigens depleted
298 was available similar to previously described [10]. Briefly, genes with low expression values and
299 invariant genes, that is, genes that were expressed in $< 5\%$ of samples or had $\text{s.d.} \leq 1$ for
300 expression (\log_2 TPM) were filtered together with non-coding genes. The soft power of 6 was
301 chosen based on goodness of fit to a scale-free network. We first annotate modules as JAVELIN
302 or angiogenesis according to the Spearman correlation between the module eigengene and
303 JAVELIN or angiogenesis ssGSEA scores (highest correlation is classified as JAVELIN or
304 angiogenesis module). Likewise, among all modules, the module with the highest Spearman
305 correlation with the fraction of neoantigens depleted was annotated as immune escape module

306 (85 genes). This 85 genes gene signature was strongly associated with PFS of Avelumab plus
307 Axitinib in JAVELIN Renal 101 (HR=1.45, P=0.02, [Extended Data Fig. 11a](#)). To further refine this
308 gene signature, we first sorted genes based on their pairwise spearman correlation ([Extended](#)
309 [Data Fig. 11b](#)) and then selected genes with the highest spearman correlation such that no genes
310 have a spearman correlation <0.6 ([Extended Data Fig. 11c](#)). This reduced the number of genes
311 to total of 12 highly correlated genes known as immune escape signature (TIMP1, PXDN,
312 COL15A1, OLFML2B, COL5A2, DLX5, SOX11, KLHDC8A, UNC5A, ADAMTS14, MMP11, FN1).
313 Several genes (ADAMTS14, MMP11, FN1, COL5A1, COL5A2 and TIMP1) in this signature has
314 previously been described as TGF- β -associated extracellular matrix genes that are linked to
315 immune evasion and immunotherapy failure [45].

316

317 **Statistical Analysis**

318 All statistical tests were performed in R. To calculate correlations, cor.test with
319 Spearman's method was used. Tests comparing distributions were performed using wilcox.test.
320 All statistical analyses were two-sided and p-values were Benjamini-Hochberg corrected.

321

322

323 **Results**

324 **The landscape of microenvironmental ITH in ccRCC**

325 To study ITH in ccRCC, we completed ultra-deep (median coverage of 360X) multi-
326 regional whole-exome sequencing and whole-transcriptome sequencing across 142 tumor
327 regions from 29 patients, including 6 untreated and 23 post ICI ([see Methods](#) and [Table S2](#)).
328 Tumor biopsies were extracted from different regions of the same primary tumor unless specified
329 ([Fig. 1a, and b, Table S2](#)). While intra-tumoral genetic heterogeneity in ccRCC is well-

330 described[46], comparatively little is known about the extent of microenvironmental heterogeneity
331 and its relationship to other molecular features of the tumor. To measure the extent of intra-
332 tumoral microenvironmental heterogeneity, we leveraged multi-regional WTS of up to 5 regions
333 from 29 patients. Using single sample gene set enrichment analysis (ssGSEA) of established
334 gene signatures, we quantified the expression of several TME gene expression signatures
335 recently proposed as biomarkers of response to ICIs and anti-angiogenic agents [47] (myeloid
336 signature [8], JAVELIN signature [10], and angiogenesis signature, [see Methods](#) and
337 [Supplementary S3](#)). We confirmed that these RNA signatures accurately quantified the
338 abundance of key immune populations using matched immunofluorescence data, including
339 statistically significant associations between CD31/angiogenesis ($p=0.0003$), CD8/JAVELIN T
340 cell signature ($p = 0.02$), and CD68/Myeloid infiltration ($p=0.0013$) ([Fig. S1](#)).

341 Microenvironmental signatures demonstrated extensive heterogeneity across tumor
342 regions from the same patient ([Fig. 2a](#)). While a small number of patients showed relatively
343 uniform immune infiltration (*e.g.*, NIVO02, [Fig. 2a](#)), the significantly more common phenomenon
344 was for patients to exhibit regions both above and below the median score for a
345 microenvironmental feature of interest (*e.g.*, angiogenesis in MR03, JAVELIN/Teffector
346 signatures in NIVO22). Using the myeloid signature (which has previously been associated with
347 poor response to ICI) as an example, we observed most patients cannot be uniquely classified to
348 myeloid enriched or depleted across all tumor regions ([Fig. 2c](#)). Given that several of these
349 signatures are under active investigation as biomarkers of response to ICI, we investigated more
350 generally how classification of regions into high/low was affected by ITH. Remarkably, in more
351 than half of the patients, clinically relevant signatures (Angiogenesis, T-effector, Myeloid, and
352 JAVELIN) could not be consistently classified as high or low ([Fig. 2b](#), 2 patients (MR05 and
353 NIVO10) were excluded since WTS data of only one region was available).

354 We hypothesized elevated microenvironmental heterogeneity may reflect the presence of
355 underlying genomic driver alterations. To test this, we leveraged multi-regional WES data
356 collected for these patients. Frequencies of established ccRCC driver alterations were in
357 agreement with a previous multi-regional study by TRACERx Renal [14] (Fig. 3a). We performed
358 unsupervised hierarchical clustering of major ccRCC driver mutations (i.e., *VHL*, *PBRM1*, *SETD2*,
359 *BAP1*) and genomic alterations enriched with metastatic disease and ICI response (HLA LOH
360 and CDKN2A/B copy number loss)[37, 43, 48], ultimately identifying two clusters (Fig. 3b, Table
361 S4). We compared the results of these clusters to aggregate, univariate measures of intra-tumoral
362 DNA, RNA, and T-cell receptor (TCR) heterogeneity. Interestingly, one cluster was characterized
363 both by an enrichment of specific genomic alterations (*SETD2* mutations, Fisher exact test
364 $P=0.002$; CDKN2A/B copy number loss, Fisher exact test $P=0.0001$; HLA LOH, Fisher exact test
365 $P=0.0007$). This same cluster of patients, which we refer to herein as “ITH-high”, had comparable
366 levels of tumor purity to the other “ITH-low” cluster, but demonstrated elevated ITH at the level of
367 somatic DNA alterations, RNA, and TCR (combined Fisher exact test $P=0.0495$). Moreover, by
368 classifying patients into previously described ccRCC evolutionary subtypes (Fig. S2), we
369 observed that *PBRM1*-driven tumors were enriched in the ITH-high cluster (on sample level,
370 Fisher exact test $P=0.0018$), in agreement with TRACERx Renal [14]. However, this finding must
371 be treated with caution due to our relatively small cohort size as well as low number of regions
372 collected in some patients. These findings were robust to the number of regions collected per
373 tumor, and we found no significant association between ITH and exposure to ICI (Fisher exact
374 test $P=0.65$, Fig. 3b). Together, our results demonstrate (1) that ITH is not restricted to genomic
375 events, but rather is pervasive in the transcriptome, microenvironment, and immune compartment
376 of ccRCC tumors, and (2) correlates with specific somatic events at the level of individual patients
377 (i.e., *PBRM1* and *SETD2* mutations, HLA LOH and CDKN2A/B loss).

378

379 **ITH-high ccRCC tumors are immunologically distinct**

380 Comparing the TME characteristics of ITH-high and ITH-low patients, we observed that
381 ITH-high tumors (defined as all regions belonging to a patient who is classified as ITH-high) were
382 characterized by high myeloid and low T cell effector (Teff) signatures (Fig. 3c). Similarly, a
383 signature associated with antigen presentation (APM)[3] was downregulated in ITH-high patients,
384 consistent with elevated levels of HLA LOH in the ITH-high subtype. To validate if genomic
385 features uniquely characterizing ITH-high tumors (HLA LOH and CDKN2A/B loss) might be more
386 generally associated with myeloid infiltration in a large, independent cohort, we obtained DNA
387 and RNA sequencing data from the TCGA KIRC study and scored samples by the presence of
388 CDKN2A/B loss, ITH (as measured by the number of clones estimated per sample using
389 PhyloWGS, see Methods), and myeloid infiltration. This analysis confirmed that in ccRCC,
390 CDKN2A/B loss was associated with higher levels of ITH ($P=3 \times 10^{-5}$) and higher myeloid infiltration
391 ($P=7 \times 10^{-5}$) (Fig. 3d). However, the association between genomic ITH and myeloid infiltration did
392 not reach statistical significance in TCGA KIRC cohort suggesting the association between
393 myeloid infiltration and ITH is likely indirect through certain genomic events such as CDKN2A/B
394 loss.

395 The findings above suggested that ITH-high tumors may be distinct in their
396 immunophenotype, including in the diversity of their T cell repertoire. We therefore investigated
397 the association between ITH and T cell diversity both peripherally and within the tumor. To do so,
398 we compared the overlap between tissue-resident and peripheral T cells. Repertoire overlap
399 analysis (Fig. S3) illustrated a high degree of shared clonotypes across different tumor regions
400 from the same patient, but a lack of shared clonotypes across patients. ITH-high patients
401 demonstrated a significantly lower peripheral TCR diversity, richness and clone count compared
402 to ITH-low patients (Fig. 3e), suggesting that elevated heterogeneity in the primary tumor is
403 associated with reduced peripheral immunologic diversity in a manner that is consistent with

404 reports in other diseases [49]. To allow a fair comparison of samples with different number of T
405 cells and account for TCR subsampling, we also studied rarefaction curves and estimated TCR
406 diversity by sequentially resampling TCR clonotypes and computing mean number of unique
407 clones [50]. Estimated diversity using rarefaction curves led to a similar conclusion confirming the
408 observed differences in the TCR diversity are unlikely to be due to artifacts in T cell subsampling
409 (Fig. S3b). Together, the above data argue that elevated molecular heterogeneity in ccRCC
410 tumors is associated with a distinct microenvironmental and immunologic phenotype.

411

412 **ICI therapy is associated with loss of putative neoantigens and HLA LOH**

413 The clinical management of ccRCC (for which pre-surgical biopsies are often not indicated
414 or used) makes serial profiling of primary tumors on therapy challenging, rendering our
415 understanding of how ICI may remodel tumor physiology incomplete. To overcome this challenge,
416 we took advantage of 16 patients from our neoadjuvant nivolumab clinical trial who had WES
417 performed on their pre-treatment biopsies. This offered a unique opportunity to interrogate both
418 genomic adaptations (including both somatic mutations as well as the expression of potentially
419 immunogenic endogenous retroviral elements, HERVs) to ICI therapy, as well as immunologic
420 changes in the T cell repertoire.

421 Focusing first on genetic alterations, we anticipated that ICI administration would lead to
422 elimination of some tumor clones and therefore a contraction in total mutation count. However,
423 we observed no consistent trend in the change of either SNV or indel mutational count following
424 ICI therapy (Fig. S4). Nevertheless, the number of non-synonymous SNVs that were predicted to
425 bind to MHC complex *in silico* was consistently reduced across all patients and all biopsies except
426 for NIVO03 (Fig. S4 and Fig. 4a). An opposite trend was observed in the number of putative non-
427 binders, suggesting a selection in favor of non-neoantigenic mutations by tumor during clonal
428 evolution (Fig. 4a).

429 In order to characterize the clonality of putative neoantigen depletion across distinct tumor
430 regions, we counted all 8-11 amino-acid-long putative neoantigens seen prior to treatment but
431 deleted in at least one biopsy after treatment. Among 7 patients with at least 4 tumor regions
432 sequenced, we observed an enrichment for putative neoantigen depletion across 4 or more sites
433 (Fig. 4b). Focusing on patient NIVO20, all 6 identified depleted putative neoantigens were deleted
434 in at least 4 regions, suggesting putative neoantigen depletion is a clonal event (Fig. 4c). Genes
435 expressing these depleted neoantigens demonstrated a 2-3-fold reduction in expression related
436 to pre-treatment biopsy (NIVO20-RA/RB/RC/RD/RE vs NIVO20-BX) (Fig. 4d). Together with the
437 data above, these observations suggest that ICI therapy in ccRCC is associated with the clonal
438 loss of mutations with elevated immunogenicity.

439 Premised on prior reports [51] of the increased immunogenicity of hydrophobic residues,
440 we sought to determine whether a selective pressure exists on certain neoantigens. We compared
441 the number of amino acids preserved versus depleted upon immunotherapy, and noticed a strong
442 selection against Phenylalanine (F, extremely hydrophobic) in favor of Arginine (R, extremely
443 hydrophilic) and Glutamic acid (E, extremely hydrophilic) in our cohort (Fig. 4e).

444 We next examined the magnitude of putative neoantigen depletion in each patient by
445 measuring the average number of putative neoantigens deleted per biopsy (i.e., the ratio of the
446 deleted neoantigens in a treated region compared to pre-treatment over the total number of pre-
447 treatment neoantigens). We observed that the fraction of neoantigens depleted was strongly
448 associated with myeloid-high regions (n = 16 patients whose pre-ICI treatment WES data was
449 available, Fig. 4f). The association between myeloid activation and neoantigen depletion
450 remained strong when total number of neoantigens depleted was used (instead of fraction) (Fig.
451 S5b) or when putative neoantigen (transcriptional) expression was taken into account (n = 7
452 patients whose pre-treatment WTS data was available, Fig. 4g) and was not affected by variation
453 in tumor purity (Fig. S5). Furthermore, the correlation between the degree of neoantigen depletion

454 and myeloid infiltration was also evident when examining different regions of individual patients,
455 where highly depleted regions were associated with the highest myeloid and lowest ImmuneScore
456 (Fig. 4g).

457 A recent study [52] identified tumor infiltrating lymphocyte specific HERV epitopes that are
458 translated, can bind to MHC I complex, and induce high-avidity cytotoxic T cells. In [52] as well
459 as other previous reports [53], over expression of HERVs on tumor cells has been reported and
460 a link to ICI response has been documented [54]. To interrogate other tumor intrinsic features
461 associated with immune response in our cohort we utilized our deep RNA sequencing (~200
462 millions read/library) to quantify HERV expression. HERVs were overexpressed in tumors
463 compared to normal tissues in our cohort (Fig. 4h), and median HERV (median of all HERV loci
464 investigated) was correlated to angiogenic expression (Fig. S7a). Notably, PBRM1 mutations,
465 which lead to further HIF upregulation [55] and angiogenic expression [56, 57], were also
466 positively associated with HERV (Fig. S7b), consistent with a recent report [58]. In agreement
467 with [54] we then confirmed the association between the median expression of different HERV
468 loci and TIL abundance (Fig. S7a). Median HERV was anti-correlated with tumor purity; however,
469 the association between HERV expression and TIL abundance remained valid even when HERV
470 expression was corrected for tumor purity (Fig. S7a). Conversely, we observed a significant
471 reduction in HERV expression an observation akin to reduction in neoantigens (Fig. 4i). Likewise,
472 we observed a strong correlation between HERV editing (i.e., change in the expression of
473 immunogenic HERV loci after treatment, see Methods) and myeloid signature further highlighting
474 the association between neoantigen depletion and myeloid enrichment (Fig. 4j). Due to the
475 limitations of HERV quantification using WTS, we could not rule out that a strong correlation
476 between HERV and TIL abundance might be due to expression of HERV on immune cells.
477 However, the expression of HERV on ccRCC tumor cells has been previously shown [59] and
478 their immunogenicity is well-established [52]. Nevertheless, rigorous determination in future

479 studies of cell-specific expression of HERVs will be critical to understanding their putative
480 association with ICI response.

481 Finally, using TCRseq of tissue resident and peripheral T cells, we investigated the impact
482 of ICI and neoantigen depletion on T cell diversity. Focusing again on patient NIVO20 where TCR
483 data of multiple regions of pre-treatment and ICI treated tumor were available, we evaluated the
484 degree of overlap between T cell clonotypes at different regions and time points i.e., pre-
485 treatment, on-therapy, and post ICI treatment (Fig. 4k). Tracking dominant tissue resident T cell
486 clonotypes, we noticed a substantial depletion of dominant T cell clones upon ICI therapy (Fig.
487 4k). This observation was mirrored across our entire cohort, where we observed a strong negative
488 association between peripheral TCR diversity and neoantigen depletion and allele specific HLA
489 loss across the entire cohort where PBMC TCRseq data was collected (Fig. 4l, m). Together, if
490 validated using future mechanistic experiments, our findings suggest that neoantigen depletion in
491 primary ccRCC tumors is associated with peripheral loss of neoantigen reactive T cells. However,
492 at this point, no causal relationship between neoantigen loss and TCR diversity can be drawn.

493

494 **Subclonal evolution underlies immune escape**

495 In order to understand the immunologic mechanisms driving subclonal evolution after ICI,
496 we investigated in detail patients whose tumors underwent subclonal immunoediting in distinct
497 regions. Strikingly, subclonal reconstruction revealed recurrent subclonal evolution of HLA LOH
498 and CDKN2A/B loss following ICI therapy (Fig. 5a). Notably, we observed HLA LOH and
499 CDKN2A/B loss co-occur in 9 patients (Fisher exact test $P=0.003$) and most tumor regions (Fisher
500 exact $P=5\times 10^{-7}$) (Fig. 5b). Strikingly, comparing the untreated and treated regions, we only
501 observed a significant immunological response (as measured by Th1 response) in regions without
502 CDKN2A/B loss or HLA LOH (Fig. 5c), suggesting that HLALOH or CDKN2A/B loss are subclonal
503 determinants of response to ICI [37, 43, 48]. This is consistent with recently published data [49]

504 indicating the loss of 9p21 - encompassing CDKN2A/B – confers a cold tumor immune
505 microenvironment and resistance to ICI. In that study, Han *et al.* [49] linked 9p21 loss to a
506 decreased abundance of B, T, CD8 T, NK cells and cytotoxic lymphocytes, and an increased
507 fractions of macrophages, as well as reduced TCR CDR3 repertoire abundance and diversity. We
508 interpret our observations to mean that immuno-editing occurs under selective pressure by which
509 certain tumor subclones transform to a less immunogenic phenotype through HLA LOH and
510 CDKN2A/B loss, and that this subclonal selection can produce a highly heterogenous TME.

511 To further shed light on the how tumor evolution can transform TME, we sought to analyze
512 the spatial distribution of TILs within the TME and their interaction with the stromal compartment
513 using immunohistochemical data. Following A.W. Zhang and colleagues [60], a dedicated
514 genitourinary pathologist classified tumor regions into 3 subtypes according to the co-localization
515 of tumor infiltrating lymphocytes and tumor cells: N-TIL (tumors sparsely infiltrated by TILs), S-
516 TIL (tumors dominated by stromal TILs), and ES-TIL (tumors with substantial levels of both
517 epithelial and stromal TILs) (Fig. 5d). We observed that an ES-TIL enriched TME is strongly
518 associated with regions with HLA LOH (ES=4, N=7, S=5 compared to ES=2, N=32, S=21 in HLA
519 intact regions, Fisher`s exact test P = 0.036) or loss of CDKN2A/B (ES=4, N=7, S=9 compared to
520 ES=2, N=32, S=17 in regions without loss of CDKN2A/B, Fisher`s exact test P = 0.03) whereas
521 N-TIL pathology is linked with regions with no HLA LOH and no CDKN2A/B loss across the cohort.
522 These findings suggest that despite abundant TILs, post-ICI ES-TIL are associated with tumor
523 clones that have evolved genetic mechanisms for evasion of the immune response (HLA LOH
524 and/or CDKN2A/B loss). However, future mechanistic studies are needed to pinpoint the primary
525 genomic event that transforms the ccRCC TME into a cold niche.

526

527 **An adverse ccRCC TME is enriched stroma and myeloid signatures**

528 We hypothesized that neoantigen depletion could be associated with a specific
529 transcriptional signature, akin to those identified in clinical trial settings as biomarkers for
530 response to ICI in ccRCC. To identify such a signature, we performed unsupervised Weighted
531 Gene Co-expression Network Analysis (WGCNA) [44] to reconstruct modules from our
532 transcriptomic samples similar to [10] (Fig. 6a). Reassuringly, we identified two gene expression
533 modules #7 and #4 reflecting established microenvironmental features associated with
534 therapeutic response in ccRCC: immune inflammatory response (“JAVELIN-like” signature) and
535 “angiogenesis-like” (Fig. 6a, b). We next assessed the correlation between the expression of each
536 WGCNA gene module and neoantigen depletion. While the JAVELIN-like and angiogenesis-like
537 modules showed no association with neoantigen depletion, module 16 demonstrated the
538 strongest association (Fig. 6a). Correlation analysis with previously known gene expression
539 signatures illustrated that module 16 (which we refer to as an “*Immune Escape*” signature) was
540 strongly associated with myeloid and stroma features of TME. The Immune Escape signature
541 also resembled a recently described pan-cancer TGF β signature derived in a previous study [45]
542 which was linked to cancer-associated fibroblasts enriched in immune evasion and
543 immunotherapy failure. However, no association between the Immune Escape signature and
544 treatment status was observed (Wilcox P=0.79) (Fig. S8).

545 To reveal the primary cellular populations driving the Immune Escape signature in the
546 ccRCC TME, we leveraged scRNAseq from multiple tumor regions, lymph node, normal kidney,
547 and peripheral blood of two ICI-naïve and four ICI-treated patients [15] (n=167283 single cells)
548 (Fig. 1c). We identified 28 clusters (Fig. 6c) using Louvain clustering [61, 62] and each cluster
549 was annotated based on our previous study [15]. As expected, scRNAseq revealed enrichment
550 of this signature in renal epithelium, tumor stroma as well as tumor associated macrophages
551 (TAMs) and monocytes (Fig. 6c). Hence, both scRNAseq and histopathological evaluation further
552 confirmed the association between Immune Escape and neoantigen depletion (Fig. 6a, Spearman

553 correlation = 0.6), ITH (Fig. 6d, Wilcox P=0.003), myeloid activation (Fig. 6b, Spearman
554 correlation = 0.8) and with stroma, and renal epithelium histopathology (Fig. 5d and Fig. 6e, f).

555

556 **Immune Escape correlates with clinical outcome to ICI therapy**

557 Several previous studies have associated signatures of Immune Escape with poor clinical
558 outcome in ICI treated patients [63]. Thus, we evaluated whether our Immune Escape signature
559 can correlate with clinical outcome to ICI treatment. We obtained publicly available RNAseq data
560 for several clinical trials including phase 3 JAVELIN Renal 101 trial [10] – a phase III randomized
561 anti-PD-L1 (avelumab) plus tyrosine kinase inhibitor (TKI, axitinib) versus multi-target TKI
562 (sunitinib), IMmotion151 [64] – a phase III trial comparing anti-PDL1 (atezolizumab) plus anti-
563 angiogenesis agent (bevacizumab) versus TKI (sunitinib) in first-line metastatic renal cell
564 carcinoma, CheckMate 009/010 – a phase I/II, aPD-1 (nivolumab) treated, and CheckMate 025 –
565 a phase III randomized mTOR inhibitor (everolimus) versus aPD-1 [9]. We stratified patients by
566 the median score (see Methods) of the 3 gene signatures obtained in our study (i.e., module
567 4/JAVELIN_like, 7/angiogenesis-like, and 16/immune escape).

568 The Immune Escape signature was strongly associated with the response to all three ICI
569 regimens (avelumab plus axitinib HR=1.53 P=0.008, atezolizumab plus bevacizumab HR=1.35
570 P=0.019 and nivolumab HR=1.45 P=0.02, Fig. 7 and Fig. S9). In contrast, the JAVELIN-like
571 inflammatory signature was strongly associated with clinical outcome to avelumab plus axitinib
572 (HR=0.64 P=0.006), but no association with clinical benefit was found between atezolizumab plus
573 bevacizumab (HR=0.82 P=0.126) or nivolumab treatment (HR=0.97 P=0.823) (Fig. 7). Similarly,
574 the angiogenesis-like signature was strongly correlated with the response to sunitinib in both
575 IMmotion151 (HR=0.48 P<0.001) and JAVELIN Renal 101 (HR=0.68 P=0.008) as expected, but
576 not with ICI-associated regimens. Associations between the Immune Escape signature and
577 therapeutic response remained valid even when thresholds other than median were used to

578 define immune escape high and low (Fig. S10). Even though the Immune Escape signature was
579 also associated with response to sunitinib in JAVELIN Renal 101, no association between
580 sunitinib response or mTOR inhibition was observed in IMmotion151 and CheckMate 025.
581 Overall, this analysis suggests that a transcriptional signature associated the tendency to lose
582 putative neoantigens after ICI is associated with response to combination ICI therapy and
583 nominates a new potential biomarker for this therapeutic regimen.

584

585 **Discussion**

586 Here we used spatiotemporal, multimodal profiling to investigate the link tumor genomics,
587 microenvironmental heterogeneity, peripheral immune response, and eventual immune escape
588 in advanced and metastatic ccRCC. The fundamental discovery of our analysis is that ITH
589 manifests well beyond the tumor genome and produces highly heterogeneous immune
590 microenvironments in the tumor. Our findings clearly suggest that the ccRCC genome and
591 microenvironment co-evolve, and that loss of putative neo-antigens (including SNVs, indels, and
592 HERVs) is associated with a qualitatively myeloid-high environment and the loss of HLA and
593 CDKN2A/B. These distinct genomic alterations are also associated with more peripheral changes,
594 i.e., reduced T cell clonal diversity in the peripheral circulation.

595 Emerging data on biomarkers of response to ICI in ccRCC has identified two potentially
596 paradoxical observations: first, that TIL abundance alone is an insufficient predictor of ICI
597 response [9], and second, that the presence of myeloid cells correlate with resistance to both ICI
598 and anti-VEGF treatments. Strikingly, we observed that high myeloid score tumors were
599 associated with neoantigen depletion which could, in principle, render ICI treatment ineffective. In
600 agreement with this, we derived a transcriptomic signature associated with neoantigen depletion
601 and Immune Escape, which was expressed in renal epithelium, tumor stroma as well as tumor
602 associated macrophages (TAMs) and monocytes. This Immune Escape signature was associated

603 with response to several ICI regimens in published clinical trials. In total, these findings suggest
604 that myeloid cells are associated with tumor clones that have evolved mechanisms to escape
605 anti-tumor immune responses. Critically, such a hypothetical model requires detailed work and
606 mechanistic validation in immunocompetent systems, which we are actively developing.

607 Why do regions with neoantigen depletion demonstrate elevation of myeloid cells but not
608 cytotoxic T cells that would presumably eliminate tumor clones? Cancer immunoediting proceeds
609 through three phases: elimination, equilibrium and escape [65]. Throughout these phases, tumor
610 immunogenicity evolves, and thereby, despite possible initial response to therapy, acquires
611 immunosuppressive mechanisms that may enable disease progression. Our data suggests that
612 myeloid-high, neoantigen-depleted tumor regions historically experienced a cytotoxic T cell
613 response, which prompted the selection of tumor clones losing neoantigens and/or
614 HLA/CDKN2A/B. Such a loss of target antigens through HLA LOH or neoantigen depletion would
615 result in loss of antigen-TCR stimulation, leading to death of the corresponding neoantigen
616 reactive T cells (Fig. 8). Importantly, as with other findings in this analysis, the association
617 between neoantigen loss and myeloid activation observed in our data remains purely correlative,
618 and future studies will be necessary to mechanistically establish how immune evasion
619 spatiotemporally evolves in ccRCC following ICI therapy.

620 Our multi-regional data also has significant implications for biomarker development. We
621 demonstrated that TME markers of response such as JAVELIN and myeloid scores can be
622 heterogenous within tumors regions (Fig. 2). This underscores the importance of accounting for
623 ITH when these signatures are used for patient selection for a specific therapy and longitudinal
624 monitoring of therapies. Given recent data that ICI may have a role in adjuvant therapy following
625 nephrectomy for high-risk disease, our data would suggest that several regions of the primary
626 tumor should be sampled specially in the presence of ITH associated genomic alterations (e.g.,
627 HLA LOH and CDKN2A/B loss). An intriguing finding was a trend towards lower ITH in ICI treated

628 tumors, even though this observation did not reach statistical significance. If validated in other
629 studies, this in part can be attributed to outgrowth of few non-immunogenic tumor subclones that
630 managed to escape immune surveillance upon ICI treatment.

631 An important limitation of this study is that TME heterogeneity of metastatic disease was
632 not assessed and may be less of an issue in biomarker development. Our study has several other
633 potential limitations including its small sample size. To overcome this shortcoming, we validated
634 several of our major findings in several independent cohorts. Another potential limitation of our
635 study is the unavailability pre-treatment multi-regional sequencing data. However, inclusion of
636 multi-regional data from 6 untreated patients allowed us to account for ITH in untreated tumors.
637 Moreover, our neoadjuvant cohort was treated with single agent nivolumab over a short course
638 which may not reflect the TME, and genomic changes induced by more potent combination
639 strategies. Finally, we portrayed the characteristics of an adverse TME which may contribute to
640 ICI resistance. Our study clearly demonstrates the interplay between genomic events and TME
641 transformation from a cytotoxic to a cold immuno-phenotype. However, these findings remain
642 purely an association of several contributing factors to ICI resistant and the exact causative
643 hierarchy of events requires further investigation.

644 In conclusion, we find distinct genomic event enriched in immune escape tumor
645 microenvironment in ccRCC both across and within tumors. Our findings have implications for
646 future biomarker development for ICI response across ccRCC and other solid tumors.

647

648 **Availability of data and materials**

649 No new code was generated. All data generated in this study are provided in Extended Data Table
650 and Figures or available upon reasonable request from corresponding author.

651

652 **Abbreviations**

653 **TCGA**: The Cancer Genome Atlas

654 **WES**: Whole-exome sequencing

655 **WTS**: Whole-transcriptome sequencing

656 **SCNA**: Somatic copy number alterations

657 **LOH**: Loss of heterozygosity

658 **ITH**: Intra-tumoral heterogeneity

659 **TCR**: T cell receptor

660 **ccRCC**: clear cell Renal Cell Carcinoma

661 **TME**: Tumor microenvironment

662 **ICI**: Immune checkpoint inhibitor

663 **TKI**: Tyrosine kinase inhibitor

664 **HERV**: Human endogenous retrovirus

665 **PBMC**: peripheral blood mononuclear cells

666 **TIL**: Tumor infiltrating lymphocytes

667 **WGCNA**: Weighted gene co-expression network analysis

668 **ssGSEA**: single sample gene set enrichment analysis

669

670

671 **References**

672 1. Liu X-D, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P:
673 **Resistance to antiangiogenic therapy is associated with an immunosuppressive**

- 674 **tumor microenvironment in metastatic renal cell carcinoma.** *Cancer immunology*
675 *research* 2015, **3**:1017-1029.
- 676 2. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N: **Molecular and genetic**
677 **properties of tumors associated with local immune cytolytic activity.** *Cell* 2015,
678 **160**:48-61.
- 679 3. Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D,
680 Ostrovnya I, Drill E, Luna A: **Tumor immune microenvironment characterization in**
681 **clear cell renal cell carcinoma identifies prognostic and immunotherapeutically**
682 **relevant messenger RNA signatures.** *Genome biology* 2016, **17**:1-25.
- 683 4. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA,
684 Postow MA, Wong P, Ho TS: **Genetic basis for clinical response to CTLA-4**
685 **blockade in melanoma.** *New England Journal of Medicine* 2014, **371**:2189-2199.
- 686 5. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt
687 C, Luber BS: **Mismatch repair deficiency predicts response of solid tumors to PD-1**
688 **blockade.** *Science* 2017, **357**:409-413.
- 689 6. Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron
690 DA, Zehir A, Jordan EJ, Omuro A: **Tumor mutational load predicts survival after**
691 **immunotherapy across multiple cancer types.** *Nature genetics* 2019, **51**:202-206.
- 692 7. Havel JJ, Chowell D, Chan TA: **The evolving landscape of biomarkers for**
693 **checkpoint inhibitor immunotherapy.** *Nature Reviews Cancer* 2019, **19**:133-150.
- 694 8. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph
695 RW, Pal SK, Reeves JA: **Clinical activity and molecular correlates of response to**
696 **atezolizumab alone or in combination with bevacizumab versus sunitinib in renal**
697 **cell carcinoma.** *Nature medicine* 2018, **24**:749-757.
- 698 9. Braun DA, Hou Y, Bakouny Z, Ficial M, Sant'Angelo M, Forman J, Ross-Macdonald P,
699 Berger AC, Jegede OA, Elagina L: **Interplay of somatic alterations and immune**
700 **infiltration modulates response to PD-1 blockade in advanced clear cell renal cell**
701 **carcinoma.** *Nature medicine* 2020, **26**:909-918.
- 702 10. Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA,
703 Uemura M, Pal SK: **Avelumab plus axitinib versus sunitinib in advanced renal cell**
704 **carcinoma: Biomarker analysis of the phase 3 JAVELIN Renal 101 trial.** *Nature*
705 *medicine* 2020, **26**:1733-1741.
- 706 11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS,
707 Sosman JA, Procopio G, Plimack ER: **Nivolumab versus everolimus in advanced**
708 **renal-cell carcinoma.** *New England Journal of Medicine* 2015, **373**:1803-1813.
- 709 12. Yarchoan M, Hopkins A, Jaffee EM: **Tumor mutational burden and response rate to**
710 **PD-1 inhibition.** *The New England journal of medicine* 2017, **377**:2500.
- 711 13. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B,
712 Soulières D, Melichar B: **Pembrolizumab plus axitinib versus sunitinib for advanced**
713 **renal-cell carcinoma.** *New England Journal of Medicine* 2019, **380**:1116-1127.
- 714 14. Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI,
715 Watkins TB, Nicol D: **Deterministic evolutionary trajectories influence primary**
716 **tumor growth: TRACERx renal.** *Cell* 2018, **173**:595-610. e511.
- 717 15. Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, Gupta S,
718 Vanderbilt C, Purohit TA, Liu M: **Single-cell sequencing links multiregional immune**
719 **landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy**
720 **efficacy.** *Cancer Cell* 2021.
- 721 16. Au L, Hatipoglu E, de Massy MR, Litchfield K, Beattie G, Rowan A, Schnidrig D,
722 Thompson R, Byrne F, Horswell S: **Determinants of anti-PD-1 response and**
723 **resistance in clear cell renal cell carcinoma.** *Cancer cell* 2021, **39**:1497-1518. e1411.

- 724 17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M,
725 Gingeras TR: **STAR: ultrafast universal RNA-seq aligner**. *Bioinformatics* 2013, **29**:15-
726 21.
- 727 18. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT,
728 Carey VJ: **Software for computing and annotating genomic ranges**. *PLoS Comput*
729 *Biol* 2013, **9**:e1003118.
- 730 19. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu Y, Roskin KM, Schwartz
731 M, Sugnet CW, Thomas DJ: **The UCSC genome browser database**. *Nucleic acids*
732 *research* 2003, **31**:51-54.
- 733 20. Love MI, Huber W, Anders S: **Moderated estimation of fold change and dispersion**
734 **for RNA-seq data with DESeq2**. *Genome biology* 2014, **15**:1-21.
- 735 21. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W,
736 Treviño V, Shen H, Laird PW, Levine DA: **Inferring tumour purity and stromal and**
737 **immune cell admixture from expression data**. *Nature communications* 2013, **4**:1-11.
- 738 22. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P,
739 Meylan E, Scholl C: **Systematic RNA interference reveals that oncogenic KRAS-**
740 **driven cancers require TBK1**. *Nature* 2009, **462**:108-112.
- 741 23. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M,
742 Alizadeh AA: **Robust enumeration of cell subsets from tissue expression profiles**.
743 *Nature methods* 2015, **12**:453-457.
- 744 24. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H,
745 Fredriksen T, Lafontaine L, Berger A: **Spatiotemporal dynamics of intratumoral**
746 **immune cells reveal the immune landscape in human cancer**. *Immunity* 2013,
747 **39**:782-795.
- 748 25. Golkaram M, Salmans ML, Kaplan S, Vijayaraghavan R, Martins M, Khan N, Garbutt C,
749 Wise A, Yao J, Casimiro S: **HERVs establish a distinct molecular subtype in stage**
750 **II/III colorectal cancer with poor outcome**. *NPJ genomic medicine* 2021, **6**:1-11.
- 751 26. Li H, Durbin R: **Fast and accurate short read alignment with Burrows–Wheeler**
752 **transform**. *bioinformatics* 2009, **25**:1754-1760.
- 753 27. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K,
754 Altshuler D, Gabriel S, Daly M: **The Genome Analysis Toolkit: a MapReduce**
755 **framework for analyzing next-generation DNA sequencing data**. *Genome research*
756 2010, **20**:1297-1303.
- 757 28. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, Del
758 Angel G, Rivas MA, Hanna M: **A framework for variation discovery and genotyping**
759 **using next-generation DNA sequencing data**. *Nature genetics* 2011, **43**:491.
- 760 29. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER,
761 Ding L, Wilson RK: **VarScan 2: somatic mutation and copy number alteration**
762 **discovery in cancer by exome sequencing**. *Genome research* 2012, **22**:568-576.
- 763 30. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, Chen X, Kim Y,
764 Beyter D, Krusche P: **Strelka2: fast and accurate calling of germline and somatic**
765 **variants**. *Nature methods* 2018, **15**:591-594.
- 766 31. Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SR, Wilkie AO, McVean G, Lunter G:
767 **Integrating mapping-, assembly-and haplotype-based approaches for calling**
768 **variants in clinical sequencing applications**. *Nature genetics* 2014, **46**:912-918.
- 769 32. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER,
770 Wilson RK, Ding L: **SomaticSniper: identification of somatic point mutations in**
771 **whole genome sequencing data**. *Bioinformatics* 2012, **28**:311-317.
- 772 33. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S,
773 Chiotti KE, McLellan M: **Scalable open science approach for mutation calling of**

- 774 **tumor exomes using multiple genomic pipelines.** *Cell systems* 2018, **6**:271-281.
775 e277.
- 776 34. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F:
777 **The ensembl variant effect predictor.** *Genome biology* 2016, **17**:1-14.
- 778 35. Amemiya HM, Kundaje A, Boyle AP: **The ENCODE blacklist: identification of**
779 **problematic regions of the genome.** *Scientific reports* 2019, **9**:1-5.
- 780 36. Shen R, Seshan VE: **FACETS: allele-specific copy number and clonal heterogeneity**
781 **analysis tool for high-throughput DNA sequencing.** *Nucleic acids research* 2016,
782 **44**:e131-e131.
- 783 37. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TB, Wilson GA, Birnbak NJ,
784 Veeriah S, Van Loo P, Herrero J: **Allele-specific HLA loss and immune escape in**
785 **lung cancer evolution.** *Cell* 2017, **171**:1259-1271. e1211.
- 786 38. Paradis E, Claude J, Strimmer K: **APE: analyses of phylogenetics and evolution in R**
787 **language.** *Bioinformatics* 2004, **20**:289-290.
- 788 39. Raynaud F, Mina M, Tavernari D, Ciriello G: **Pan-cancer inference of intra-tumor**
789 **heterogeneity reveals associations with different forms of genomic instability.**
790 *PLoS genetics* 2018, **14**:e1007669.
- 791 40. Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen Y-JJ, Chitre AS, Chiang EY,
792 Iftikhar H, O'Gorman WE, Au-Yeung A: **Peripheral T cell expansion predicts tumour**
793 **infiltration and clinical response.** *Nature* 2020, **579**:274-278.
- 794 41. Nazarov V: **immunarch. bot & Eugene Rumynskiy. immunomind/immunarch: 0.6. 5:**
795 **Basic single-cell support.** Zenodo; 2020.
- 796 42. Horn HS: **Measurement of" overlap" in comparative ecological studies.** *The*
797 *American Naturalist* 1966, **100**:419-424.
- 798 43. Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LG, Riaz N, Lenz
799 TL, Chan TA: **Evolutionary divergence of HLA class I genotype impacts efficacy of**
800 **cancer immunotherapy.** *Nature medicine* 2019, **25**:1715-1720.
- 801 44. Langfelder P, Horvath S: **WGCNA: an R package for weighted correlation network**
802 **analysis.** *BMC bioinformatics* 2008, **9**:1-13.
- 803 45. Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD: **TGF- β -associated**
804 **extracellular matrix genes link cancer-associated fibroblasts to immune evasion**
805 **and immunotherapy failure.** *Nature communications* 2018, **9**:1-10.
- 806 46. Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JL, Nicol D, O'Brien T, Larkin
807 J, Horswell S: **Tracking cancer evolution reveals constrained routes to metastases:**
808 **TRACERx renal.** *Cell* 2018, **173**:581-594. e512.
- 809 47. Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnya I, Chen
810 Y-B, Reuter V: **Transcriptomic profiling of the tumor microenvironment reveals**
811 **distinct subgroups of clear cell renal cell cancer: data from a randomized phase III**
812 **trial.** *Cancer discovery* 2019, **9**:510-525.
- 813 48. Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A: **Tumor**
814 **CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance.**
815 *JNCI: Journal of the National Cancer Institute* 2018, **110**:677-681.
- 816 49. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang
817 R: **9p21 loss confers a cold tumor immune microenvironment and primary**
818 **resistance to immune checkpoint therapy.** *Nature communications* 2021, **12**:1-19.
- 819 50. Laydon DJ, Bangham CR, Asquith B: **Estimating T-cell repertoire diversity:**
820 **limitations of classical estimators and a new approach.** *Philosophical Transactions*
821 *of the Royal Society B: Biological Sciences* 2015, **370**:20140291.
- 822 51. Riley TP, Keller GL, Smith AR, Davancaze LM, Arbuiso AG, Devlin JR, Baker BM:
823 **Structure based prediction of neoantigen immunogenicity.** *Frontiers in immunology*
824 2019, **10**:2047.

- 825 52. Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvain N, Michel E, Boulos RE,
826 Estornes Y, Valladeau-Guilemond J: **Identification of shared tumor epitopes from**
827 **endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer**
828 **immunotherapy.** *Science Advances* 2022, **8**:eabj3671.
- 829 53. Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG,
830 Serody JS, Beckermann KE: **Endogenous retrovirus expression is associated with**
831 **response to immune checkpoint blockade in clear cell renal cell carcinoma.** *JCI*
832 *insight* 2018, **3**.
- 833 54. Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A,
834 Ganesan S, Bhanot G, Wallen EM: **Endogenous retroviral signatures predict**
835 **immunotherapy response in clear cell renal cell carcinoma.** *The Journal of clinical*
836 *investigation* 2019, **128**:4804-4820.
- 837 55. Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S,
838 Oyama T, Takeda S: **The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear**
839 **cell renal cell carcinoma.** *Cell reports* 2017, **18**:2893-2906.
- 840 56. Hakimi AA, Attalla K, DiNatale RG, Ostrovnya I, Flynn J, Blum KA, Ged Y, Hoen D,
841 Kendall SM, Reznik E: **A pan-cancer analysis of PBAF complex mutations and their**
842 **association with immunotherapy response.** *Nature communications* 2020, **11**:1-11.
- 843 57. Liu X-D, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H,
844 Beckermann KE: **PBRM1 loss defines a nonimmunogenic tumor phenotype**
845 **associated with checkpoint inhibitor resistance in renal carcinoma.** *Nature*
846 *communications* 2020, **11**:1-14.
- 847 58. Zhou M, Leung JY, Gessner KH, Hepperla AJ, Simon JM, Davis IJ, Kim WY: **PBRM1**
848 **inactivation promotes upregulation of human endogenous retroviruses in a HIF-**
849 **dependent manner.** *Cancer immunology research* 2022.
- 850 59. Zhang Y, Narayanan SP, Mannan R, Raskind G, Wang X, Vats P, Su F, Hosseini N,
851 Cao X, Kumar-Sinha C: **Single-cell analyses of renal cell cancers reveal insights**
852 **into tumor microenvironment, cell of origin, and therapy response.** *Proceedings of*
853 *the National Academy of Sciences* 2021, **118**.
- 854 60. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T,
855 Little N, de Souza CP, Laan S: **Interfaces of malignant and immunologic clonal**
856 **dynamics in ovarian cancer.** *Cell* 2018, **173**:1755-1769. e1722.
- 857 61. Levine JH, Simonds EF, Bendall SC, Davis KL, El-ad DA, Tadmor MD, Litvin O,
858 Fienberg HG, Jager A, Zunder ER: **Data-driven phenotypic dissection of AML**
859 **reveals progenitor-like cells that correlate with prognosis.** *Cell* 2015, **162**:184-197.
- 860 62. Xu C, Su Z: **Identification of cell types from single-cell transcriptomes using a**
861 **novel clustering method.** *Bioinformatics* 2015, **31**:1974-1980.
- 862 63. Hegde PS, Chen DS: **Top 10 challenges in cancer immunotherapy.** *Immunity* 2020,
863 **52**:17-35.
- 864 64. Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B,
865 Liu L-F, Leng N, Abbas AR: **Molecular subsets in renal cancer determine outcome**
866 **to checkpoint and angiogenesis blockade.** *Cancer Cell* 2020, **38**:803-817. e804.
- 867 65. O'Donnell JS, Teng MW, Smyth MJ: **Cancer immunoediting and resistance to T cell-**
868 **based immunotherapy.** *Nature reviews Clinical oncology* 2019, **16**:151-167.

869

870

871

872 **Acknowledgements**

873 **Funding**

874 We thank members of the Chan lab for their suggestions and critical reading of the manuscript.

875 We acknowledge funding sources including NIH R01 CA205426 (T.A.C.), NIH R35 CA232097

876 (T.A.C.), DOD grant KC180165, NIH R01 DE027738 (to L.G.T.M.), the NIH/NCI Cancer Center

877 Support Grant P30 CA008748 (to MSKCC), P30 core grants (to MSKCC), Ludwig institute

878 (A.A.H.), Weiss family fund (A.A.H.), Department of Defense (A.A.H.) and Illumina Inc.

879

880 **Contributions**

881 M.G. performed data analysis and wrote the manuscript with input from all authors. M.G., A.A.H.,

882 T.A.C., and E.R. conceived the study and contributed to data interpretation. F.K., E.R., C.T., V.M.,

883 S.Z., C.Z., and R.M. assisted with analytical methodology development and bioinformatics

884 support. M.L.S., R.V., L.L., T.P., and J.G. contributed to DNA, RNA, and TCR sequencing. R.J.M.,

885 M.I.C., P.R., J.C., L.G.T.M., and M.H.V. cared for patients analyzed in the study. K.A.B. and

886 R.G.N. handled patient samples. R.G.N. collected and analyzed clinical metadata. S.G. and Y.C.

887 analyzed H&E images. All authors read and approved the manuscript.

888

889 **Ethics declarations**

890 **Ethics approval and consent to participate**

891 Informed consent and institutional review board approval were acquired at Memorial Sloan

892 Kettering Cancer Center (MSK).

893 **Consent for publication**

894 Not applicable.

895 **Competing interests:** M.G., R.V., M.L.S., J.G., T.P., R.M., C.Z., S.Z., L.L., are current employees
896 and shareholders of Illumina Inc. T.A.C. and L.G.T.M. are inventors on a patent held by Memorial
897 Sloan Kettering related to the use of TMB in cancer immunotherapy. MSK has licensed the use
898 of TMB for the identification of patients that benefit from immune checkpoint therapy to PGDx.
899 L.G.T.M. reports laboratory research funding from AstraZeneca. T.A.C. is a co-founder of
900 Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant
901 funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has
902 served as an advisor for Bristol-Myers Squibb, Illumina, Eisai, and An2H. R.J.M. reports
903 consulting fees from Aveo, Calithera, Eisai, Eli Lilly, EMD Serono, Genentech, Merck, Novartis
904 AG, Pfizer, and Roche, and contracted research to employer MSKCC for Bristol Myers Squibb,
905 Eisai, Exelixis, Genentech, Merck, Pfizer, and Roche. A.A.H. is on the advisory board for Merck.
906 M.H. receives commercial research grants from Bristol-Myers Squibb, Pfizer and
907 Genentech/Roche, honoraria from Novartis, Bristol-Myers Squibb, travel/accommodation from
908 Astra Zeneca, Eisai, Novartis and Takeda, and is a consultant/advisory board member for Alexion
909 Pharmaceuticals, Aveo, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai,
910 GlaxoSmithKline, Merck, Natera; Onquality Pharmaceuticals; Novartis and Pfizer. Other authors
911 declare no competing interests.

912

913 **Figures and Tables**

914 **Figure 1. Patient characteristics and study design.** a) Multi-regional multi-omics was
915 performed on 29 patients. b) In total, 6 out of 29 patients were untreated and the rest were treated
916 with ICI or in combination with TKI. TCRseq of PBMC was performed at 4 time points on therapy
917 for a subset of patients. In addition, pathological review was performed to assign N-TIL (tumors
918 sparsely infiltrated by TILs), S-TIL (tumors dominated by stromal TILs), and ES-TIL (tumors with

919 substantial levels of both epithelial and stromal TILs) classes to a subset of patients. **c)**
920 Additionally, scRNAseq data for 6 patients were available from [15].

921
922 **Figure 2. TME ITH in ccRCC. a)** Intra-tumoral heterogeneity of several gene expression
923 signatures across multiple tumor regions. Radar charts show Z-score of each feature normalized
924 across the cohort. Min and max radius for each feature in each panel represent min and max of
925 that feature across the cohort. **b)** For each gene signature, the number of patients who were
926 classified as high or low or a mixture of high and low across tumor regions are shown. Two
927 patients (MR05 and NIVO10) were excluded since WTS data of only one region was available.
928 Also, pre-treatment regions of ICI treated patients were excluded to avoid treatment-related
929 effects in these signatures. **c)** Intra-tumoral heterogeneity of myeloid score observed across
930 multiple regions of tumors of patients in this study.

931
932 **Figure 3. Landscape of ITH in ccRCC. a)** Oncoprint of key ccRCC driver mutations and copy
933 number alterations for all regions of all 29 patients in this cohort. Margin shows comparison
934 between mutation frequency observed in this cohort and TRACERx Renal. **b)** We have performed
935 unsupervised hierarchical clustering of genomic features including patient level presence or
936 absence of a small variant in VHL, PBRM1, SETD2, BAP1 (most commonly mutated genes) as
937 well as loss of heterozygosity in HLA genes as well as 9p (which includes CDKN2A/B) SCNA
938 which are known to affect ICI response. Heatmap shows ITH high vs low classification across
939 data type. Annotation illustrates evolutionary subtypes and treatment status of patients. A patient
940 is annotated as wildtype if all regions are wild type for that alteration. Cases where ITH score
941 could not be calculated due to lack of sufficient number of biopsies are shown in gray pixels. CIN:
942 chromosome instability. **c)** Association between antigen presentation machinery (APM), effector
943 T cell (Teff) and myeloid gene signatures and ITH. Wilcox P, False Discovery Rate (FDR) and

944 Linear Mixed Effect (LME) P shown. **d)** Intra-tumoral heterogeneity and myeloid score are
945 associated with CDKN2A/B loss in TCGA KIRC cohort. **e)** ITH low patients show a significantly
946 higher TCR diversity, richness and clone count.

947

948 **Figure 4. The landscape of heterogeneity of neoantigen depletion.** **a)** Change in the number
949 of non-synonymous binder SNVs (predicted *in silico*) and non-synonymous non-binder SNVs
950 compared to pre-treatment. Reduction in only putative neoantigens illustrates selective pressure
951 and immunoediting. One sample Wilcox test P (compared to zero) is shown. **b)** Clonality of
952 neoantigen depletion. Only strong binders are shown. **c, d)** Immunoediting in an HLA-intact
953 patient NIVO20 through reduced neoantigen expression. NKA/NKB/NKC (shown in RED) are
954 normal adjacent tissues 1cm, 2cm, and 4cm away from the center of the tumor; BX (shown in
955 blue) represents pre-treatment biopsy; RA/RB/RC/RD/RE (shown in green) illustrate 5 tumor
956 regions from the treated tumor sample. **e)** Immunoediting with amino acid resolution. Higher
957 Phenylalanine (F) depletion compared to Glutamic Acid (E) and Arginine (R) suggests immune
958 selection. **f)** Association between putative neoantigen depletion and myeloid activation across all
959 regions of patients where pre-treatment WES data was available (n = 16 patients). **g)** Association
960 between the fraction of expressed putative neoantigens depleted and immune signatures. In **(g)**
961 correlations are calculated across different regions of the same patient, for all patients with >3
962 treated as well as pre-treatment RNA samples were available (n = 7 patients). **h, i)** HERVs are
963 enriched in tumors compared to normal samples and are associated with treatment. **j)** HERV
964 depletion association with myeloid signature. **k)** Circos plot (left) illustrates the fraction of shared
965 T cell clonotypes between tissue and different time points on therapy. Ribbons connecting
966 different regions of the tumor are scaled based on clonotype overlap. (right) clonotype tracking of
967 dominant untreated T cell clones in treated regions of patient NIVO20. The color of each ribbon
968 shows different T cell clones, and the width is scaled corresponding to the frequency of that clone.

969 Tissue data consists of 5 tumor regions after treatment (RA/RB/RC/RD/RE), one single normal
970 adjacent (NKC), and one tumor region pre-treatment (BX). Likewise, PBMC data points on
971 treatment are NIVO20-68, -54, -40, -12. **l, m**) TCR diversity is negatively associated with
972 neoantigen depletion and HLA LOH.

973

974 **Figure 5. Branch evolution demonstrates immune evasion.** **a)** Evolutionary tree illustrates
975 tumors can exploit concurrent HLA LOH and CDKN2A/B loss to escape immune surveillance. **b)**
976 Co-occurrence of HLA LOH and CDKN2A/B can be seen both across regions and patients. **c)**
977 Differential immune response to ICI therapy in patients with CDKN2A/B loss or HLA LOH or
978 belonging to ITH high subtype. **d)** Regions of tumor associated with immune escape depict a
979 distinct pathology where colocalization of TILs and stroma can be observed.

980

981 **Figure 6. Immunoediting correlates with stroma and myeloid signatures.** **a)** WGCNA
982 identifies gene expression modules associated with inflammation (“JAVELIN-like”), angiogenesis,
983 and Immune Escape. Gene dendrogram was first generated and then modules were extracted
984 using dynamic tree cutting (top). Modules were annotated by comparing the correlation between
985 the module eigengenes and previously known gene signatures describing different phenotypes
986 (bottom). **b)** Modules 7 (black), 4 (salmon), and 16 (magenta) are associated with previously
987 described signatures, JAVELIN, angiogenesis and myeloid/stroma. **c)** scRNAseq demonstrates
988 the cell type enrichment of Immune Escape signature in ccRCC patients. Different colors
989 represent different cell types inferred from scRNAseq data. UMAP plot illustrates single cells
990 collected from all 6 patients including treated and untreated patients. Computational extracted
991 clusters were annotated as previously described [15] **d, e)** Association between ITH groups,
992 Immune Escape signature and N/S/ES pathologies. **f)** These regions demonstrate an elevated

993 Immune Escape gene signature in NIVO21. RA, RB, RC, RD, and RE denote different regions of
994 a tumor sample.

995

996 **Figure 7. Association between immune escape and clinical outcome to checkpoint**
997 **blockade.** Survival analysis shows the association between gene signatures obtained in this
998 study and clinical outcome of different independent retrospective trials. **a)** Immune Escape and
999 JAVELIN-like signatures are associated with PFS in patients treated Avelumab plus Axitinib in
1000 JAVELIN Renal 101 cohort. **b)** Immune Escape signature, but not the JAVELIN-like signature,
1001 correlates with the response to Atezolizumab plus Bevacizumab in IMmotion151 but not JAVELIN
1002 signature. **c)** Immune Escape signature, but not the JAVELIN-like signature, correlates with the
1003 efficacy of anti-PD1-treatment in CheckMate 009, 010, 025.

1004

1005 **Figure 8. A hypothetical model for spatiotemporal evolution of ccRCC links ITH to immune**
1006 **escape and adverse TME.** Cancer cell death, potentially by cytotoxic killing, early in tumor
1007 evolution selects for tumor clones with HLA LOH and/or CDKN2A/B loss. This promotes the
1008 evolution of a TME depleted of antigen-specific T cells and enriched for myeloid cells.

1009

1010 **Supplementary Figure Legends**

1011 **Fig. S1. Validation of TME associated gene signatures using IF.** Myeloid signature correlates
1012 with CD11b/CD68 markers. CD31 endothelial and CD8 T cell markers are correlated with
1013 Angiogenesis and JAVELIN signatures.

1014 **Fig. S2. ccRCC evolutionary subtypes and their association with angiogenic TME score.**

1015 **Fig. S3. Clonotype overlap analysis.** **a)** Hierarchical clustering of TCR clonotypes across
1016 different regions of patients where tissue TCRseq data was available. **B)** Rarefaction analysis of

1017 ITH high vs ITH low patients **c)** Circos plot illustrates the fraction of shared T cell clonotypes
1018 between tissue and different time points on therapy. Ribbons connecting different regions of the
1019 tumor are scaled based on clonotype overlap. Labels show patient ID followed by time to
1020 nephrectomy (e.g., NIVO09-7: patient NIVO09 at 7 days to nephrectomy) **d)** Number of CDR3
1021 clone counts shown for all samples where TCR seq was performed.

1022 **Fig. S4. Boxplots show total and change compared to pre-treatment (when sample was**
1023 **available) for mutational count, and neoantigen count across different regions of all**
1024 **patients. Count change is shown only for 16 patients whose pre-treatment WES data was**
1025 **available.**

1026 **Fig. S5. Association between neoantigen loss and myeloid signature. a)** No association
1027 between TMB and tumor purity (FACETS) was observed **b)** Association between total number of
1028 neoantigens depleted and myeloid signature. **c)** The fraction of mutations or neoantigens depleted
1029 is not correlated with tumor purity for samples with tumor purity larger than 0.3; however, the
1030 association between myeloid signature and neoantigen depletion remains strong even after
1031 excluding samples with low purity. **d)** Association between immune elimination and escape with
1032 myeloid signature.

1033 **Fig. S6. Comparison between SNPs neoantigen depletion and INDEL depletion.**

1034 **Fig. S7. Treatment impact of HERV association with TME. a)** Association between HERV
1035 expression and immune signatures. **b)** PBRM1 mutations are associated with elevated HERV
1036 expression. **c)** Association between ClearCode34 classes and HERV expression. **d)** Association
1037 between ClearCode34 classes and neoantigen depletion.

1038 **Fig. S8. Association between immune escape signature and treatment.**

1039 **Fig. S9. Validation of escape signature in independent cohorts (IMmotion151).** a) Escape
1040 signature is associated with improved survival in patients treated with ICI but not sunitinib. b)
1041 Escape signature is associated with CDKN2A/B alteration in Immotion151.

1042 **Fig. S10. Relationship between escape gene signature and treatment outcome in different**
1043 **clinical trials.** HRs are calculated for each threshold for ICI or ICI in combination with TKI arms
1044 in JAVELIN Renal 101, IMmotion151, and CheckMate 009, 010, 025.

1045 **Fig. S11. Refinement of immune escape gene signature.** a) 85 genes immune escape gene
1046 signature is strongly associated with response to Avelumab plus Axitinib in JAVELIN Renal 101
1047 trial. b) Pairwise spearman correlation between 85 genes in module 16 (immune escape). c)
1048 Refinement of 85 genes into 12 genes with the highest pairwise spearman correlation.

1049

1050

1051 **Supplementary Materials**

1052

1053 **Supplementary Tables**

1054 **Table S1:** Data availability.

1055 **Table S2:** Patient characteristics and relevant clinical data.

1056 **Table S3:** WTS related gene signatures.

1057 **Table S4:** ITH classification.

Figure 1




Figure 2




Figure 3




Figure 4






Figure 5


a




NIVO21: ITH high; PBRM1→SETD2




NIVO12: ITH high; VHL monodriver NIVO03: ITH high; PBRM1→PI3K SC14: ITH high; PBRM1→PI3K




b




c




d



N



S



ES

Figure 6





Figure 7

a


RJ Motzer et al. (JAVELIN Renal 101) n=354

Avelumab plus Axitinib



RJ Motzer et al. (JAVELIN Renal 101) n=372


Sunitinib



b


RJ Motzer et al. (IMmotion151) n=407

Atezolizumab plus Bevacizumab



RJ Motzer et al. (IMmotion151) n=416


Sunitinib



c

DA Braun et al. (CheckMate 009, 010, 025) n=181

Anti-PD1-treatment



DA Braun et al. (CheckMate 009, 010, 025) n=130

mTOR inhibition









Figure 8




Extended Data Fig. 1




Extended Data Fig. 2


BAP1 driven




Multiple clonal driver




PBRM1 → PI3K




PBRM1 → SCNA




PBRM1 → SETD2




VHL monodriver




VHL wildtype




Angiogenesis





Extended Data Fig. 3








Extended Data Fig. 4




Extended Data Fig. 5



c only samples with tumor purity (FACETS) > 0.3 included




Extended Data Fig. 6




Extended Data Fig. 7

a


Association between immune signatures and median HERV expression (not corrected for purity)




Association between immune signatures and median HERV expression (corrected for purity)




b



c




d



Extended Data Fig. 8

a

Wilcox P=0.79




Extended Data Fig. 9


a

IMmotion151

Wilcox P=0.04679



Wilcox P=0.6797




Atezolizumab plus bevacizumab arm

Sunitinib arm

b


Wilcox P=0.06765

CDKN2A/B alteration (IMmotion151)




Extended Data Fig. 10

**immune escape signature associated
with poor survival
(JAVELIN RENAL 101)**




RJ Motzer *et al.* (JAVELIN Renal 101) n=354
Avelumab plus Axitinib

**immune escape signature associated
with poor survival
(IMmotion151)**



RJ Motzer *et al.* (IMmotion151) n=407
Atezolizumab plus bevacizumab

**immune escape signature associated
with poor survival
(CheckMate 009, 010, 025)**



DA Braun *et al.* (CheckMate 009, 010, 025) n=181
Anti-PD1-treatment

Extended Data Fig. 11

